Search Results - "Patterson, A.V"

OC-0236: DTP-006: a novel, orally bioavailable hypoxia-activated prodrug by Niemans, R, Yaromina, A, Theys, J, Ashoorzadeh, A, Anderson, R, Bull, M, Guise, C, Hsu, H.L, Abbattista, M, Mowday, A, Patterson, A.V, Smaill, J.B, Ackerley, D.F, Dubois, L, Lambin, P

Get full text

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954 by Prosser, G.A., Patterson, A.V., Ackerley, D.F.

“…CB1954 is an anti-cancer prodrug that can be reduced at either of two nitro groups to form cytotoxic metabolites. We describe here two efficient and previously…”
Get full text

1015 POSTER Evaluation of the Role of the Novel Glucose-phosphorylating Enzyme ADP-dependent Glucokinase in Human Tumour Cell Lines Using Zinc Finger Nuclease Gene Knockouts by Richter, S, Patterson, A.V, Stowell, K.M, Ronimus, R.S, Wilson, W.R

Get full text

474 POSTER Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models by Singleton, R.S, Pullen, S.M, Ferry, D.M, Guise, C.P, Patterson, A.V, Wilson, W.R

Get full text

300 POSTER Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104 by Singleton, D.C, Syddall, S.P, Bai, S.Y, Li, D, Denny, W.A, Wilson, W.R, Patterson, A.V

Get full text

305 POSTER Structure–activity relationships for lipophilic dinitrobenzamide mustards as prodrugs for Escherichia coli NfsB nitroreductase by Sydall, S, Ashoorzadeh, A, Atwell, G.A, Smaill, J.B, Wilson, W.R, Denny, W.A, Patterson, A.V

Get full text

473 POSTER The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase) by Patterson, A.V, Guise, C.P, Abbattista, M, van Leeuwen, W, Pullen, S.M, Ferry, D.M, Denny, W.A, Guilford, P, Wilson, W.R

Get full text

OC-0591: Hypoxic cell killing by SN36506, a novel hypoxia-activated prodrug by Niemans, R., Yaromina, A., Theys, J., Ashoorzadeh, A., Anderson, R., Bull, M., Guise, C., Hsu, H.L., Abbattista, M., Mowday, A., Patterson, A.V., Smaill, J.B., Dubois, L., Lambin, P.

Get full text

EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug by Niemans, R., Yaromina, A., Theys, J., Marcus, D., Ashoorzadeh, A., Abbattista, M., Mowday, A., Biemans, R., Lieuwes, N., Deschoemaeker, S., Heyerick, A., Guise, C., Smaill, J.B., Patterson, A.V., Dubois, L., Lambin, P.

Get full text

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 by Prosser, G.A., Copp, J.N., Syddall, S.P., Williams, E.M., Smaill, J.B., Wilson, W.R., Patterson, A.V., Ackerley, D.F.

“…Gene-directed enzyme prodrug therapy (GDEPT) aims to achieve highly selective tumor-cell killing through the use of tumor-tropic gene delivery vectors coupled…”
Get full text

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs by Copp, J.N., Williams, E.M., Rich, M.H., Patterson, A.V., Smaill, J.B., Ackerley, D.F.

“…Engineering of enzymes to more efficiently activate genotoxic prodrugs holds great potential for improving anticancer gene or antibody therapies. We report the…”
Get full text

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954 by Swe, P.M., Copp, J.N., Green, L.K., Guise, C.P., Mowday, A.M., Smaill, J.B., Patterson, A.V., Ackerley, D.F.

“…Phase I/II cancer gene therapy trials of the Escherichia coli nitroreductase NfsB in partnership with the prodrug CB1954…”
Get full text

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-[411.sup.NTR] by Singleton, D.C, Li, D, Bai, S.Y, Syddall, S.P, Smaill, J.B, Shen, Y, Denny, W.A, Wilson, W.R, Patterson, A.V

Get full text

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation by Greco, O, Marples, B, Dachs, G.U, Williams, K.J, Patterson, A.V, Scott, S.D, Hsieh, J.T

Get full text

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation by Kim, Joo-Young, West, C.M.L., Valentine, H., Ward, T.H., Patterson, A.V., Stratford, I.J., Roberts, S.A., Hendry, J.H.

“…RH1 is a new bioreductive agent that was developed as a cytotoxic agent with selectivity for tumour cells expressing high levels of the enzyme DT-diaphorase…”
Get full text

496 Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins by Wilson, W.R., Pullen, S.M., Degenkolbe, A., Ferry, D.M., Helsby, N.A., Hicks, K.O., Atwell, G.J., Yang, S., Denny, W.A., Patterson, A.V.

Get full text